Business
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Presentation by Massachusetts General Chair of Neurology Merit Cudkowicz, MD, shows both positive clinical effects and consistent trend toward impact on Neurofilament biomarker levels\nCAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (\"NeuroSense\"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data. In addition to the positive clinical outcomes, the study also demonstrated a positive trend toward impact on Neurofilament (NfL) levels.\n\nThe presentation, titled, \"PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary and Secondary Endpoints in the Phase 2b PARADIGM Trial,\" was presented yesterday as an Emerging Science presentation by Merit Cudkowicz, M.D., M.Sc., chair of neurology and Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. The study showed that PrimeC, a novel formulation of specific doses of ciprofloxacin and celecoxib, met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0.03) in the per-protocol population. Further, the data showed supporting trends in biomarkers, specifically Neurofilament. \nAlon Ben-Noon, CEO of NeuroSense commented, \"It is gratifying that these data have been validated by the prestigious American Academy of Neurology and presented by Dr. Cudkowicz. We look forward to continued work with PrimeC for ALS and believe that there is a significant opportunity to provide a potential new approach to address this devastating disease.\"\nAbout NeuroSense\nNeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to...